Health Care

MacroGenics Gets Downgraded Following Disappointing Prostate Cancer Trial Results: 'We Were Surprised By Reported Deaths'
From Hype To Reality, AI Reshapes Pharmaceutical Industry Across Drug Discovery To Marketing - Stocks To Watch
Fertility Solutions-Focused Progyny Stock Sinks After Soft Guidance; Analyst Says 'Can No Longer Underwrite Sustained Healthy Growth In Forecasts'
From Hype To Reality, AI Reshapes Pharmaceutical Industry Across Drug Discovery To Marketing - Stocks To Watch
Fertility Solutions-Focused Progyny Stock Sinks After Soft Guidance; Analyst Says 'Can No Longer Underwrite Sustained Healthy Growth In Forecasts'
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
A $1.8 Trillion Market Is Poised To Explode As Personal Health Spending Catches Fire

Health Care Recent News

MacroGenics Shares Tumble After Reporting Adverse Events, Multiple Deaths In Cancer Drug Trial
Latest interim data from TAMARACK Phase 2 study by MacroGenics unveils insights into vobramitamab duocarmazine targeting B7-H3 in metastatic prostate cancer. Despite responses, notable safety concerns reported.
What's Going On With Medical Therapeutic Firm Aethlon Medical On Friday?
Aethlon Medical unveils results in removing extracellular vesicles (EVs) from plasma. Preclinical evidence supports upcoming phase 1 trials for solid tumor patients undergoing anti-PD-1 monotherapy.
FDA Delays 'Important' Moderna Vaccine Review: William Blair Says 2025 Growth, '2026 Breakeven Story' Depends On It
FDA update: Moderna's BLA for mRNA-1345, RSV vaccine, may face delay past May 12 deadline. But no safety concerns reported.
Apple's Vision Pro Headset Becomes Surgeons' Tool Of Choice For 'Keyhole' Surgeries
Apple Vision Pro mixed-reality headset is gaining popularity among surgeons in India, facilitating over 30 laparoscopic surgeries with enhanced precision and real-time data access.
Neuralink Rival Backed By Jeff Bezos And Bill Gates Broadens Horizons With Plans To Treat Parkinson's, Epilepsy
Unlike Neuralink, Synchron's approach does not require brain surgery.
Nvidia-Backed Recursion Pharmaceuticals Stock Is Up On Q1 Earnings: Everything You Need To Know
Recursion reported first-quarter revenue of $13.491 million, which beat analyst estimates of $12.65 million, according to Benzinga Pro. The company reported a quarterly loss of 39 cents per share, which beat estimates for a loss of 42 cents per share.
Analysts' Varied Perspectives On CytomX's CX-904 Cancer Study: Safety Profile But Caution in Pancreatic Cancer
Initial data from CytomX Therapeutics' CX-904 Phase 1a study shows safety and anti-cancer activity in heavily pretreated patients with advanced metastatic solid tumors. Reductions observed, especially in pancreatic cancer, with stable disease maintained.
Cannabis Is Now The Best Solution For Migraine Headaches According To 3 New Medical Studies
This article was originally published on Cannabis.net and appears here with permission. Migraine sufferers drop prescription drugs at record pace and switch to cannabis for headache pain!
Change Healthcare Cyberattack: GoodRx Expects Low Single Digit Million-Dollar Impact In 2024
GoodRx's Q1 earnings: $0.08 EPS, sales hit $197.88 million, beating expectations fueled by prescription transactions and pharma solutions. Q2 forecast: ~$200 million revenue, optimistic 2024 outlook.
What's Going On With Dermatitis-Focused RAPT Therapeutics Stock On Thursday?
RAPT Therapeutics closes Phase 2 trials for zelnecirnon in atopic dermatitis & asthma following FDA clinical hold due to liver failure.
Japan's Takeda Pharma Outlines $900M Overhaul To Boost Growth, As 2023 Profit Fall Over 50%
Takeda Pharmaceutical (NYSE: TAK) reveals fiscal year 2023 results & restructuring plan. Revenue up 5.9%, net profit down 54.6%. Expecting operating profit of 225 billion yen in 2024.
A Look at Pharma ETFs Post Q1 Earnings
The first-quarter results of the healthcare sector have been unimpressive, with earnings of 78% of the sector participants that have reported so far down 31.2% despite 4.4% revenue growth. The earnings beat ratio of 93.9% and the revenue beat ratio of 75.8% are assuring, though.
Perrigo Q1 Earnings Surpass, Sales Miss Estimates
Perrigo Company plc (NYSE: PRGO) reported adjusted earnings of 29 cents per share in the first quarter of 2024, beating the Zacks Consensus Estimate of 24 cents. Earnings were down 35.6% year over year, primarily due to a negative financial impact of 30 cents per share from infant formula.

Explore Benzinga's Financial Tools

Find Stocks Tailored to Your Trading Interests
Find Stocks Tailored to Your Trading Interests
Benzinga Pro offers a real-time newsfeed as headlines break on earnings releases, analyst ratings, rumors, the biggest movers, and many more actionable alerts.

Compare Benzinga's Favorite Stock Brokers

Claim Exclusive Offers

Compare Benzinga's Favorite Cryptocurrency Brokers

Claim Exclusive Offers